"Dapagliozin and Pioglitazone tablet combo is taken once daily, providing a dual-action
approach to managing type 2 diabetes and simplies the overall management of the
condition New Delhi: Expanding its portfolio from manufacturing to marketing
drugs, a CDMO Akums Drugs and Pharmaceuticals, has launched
Dapagliflozin + Pioglitazone tablets; an advanced combination therapy
indicated for the management of Type-2 diabetes. The DCGI approved dualaction formulation offers a
more potent solution for
individuals struggling with
existing metformin-based
regimens and it goes beyond
glycemic control, overcoming
broader obstacles associated
with diabetes care, the company stated.
Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, aids
in eliminating excess glucose via urine whereas, Pioglitazone, is a is a
thiazolidinedione which augments insulin sensitivity in key tissues, such
as muscles and the liver, helping combat the root issue of insulin
resistance. Commenting on the launch, Sandeep Jain, Managing Director of Akums
Drugs and Pharmaceuticals, said, “The rise in diabetes cases in our
country calls for novel and accessible solutions and.. requires a
collaborative effort between healthcare providers and pharmaceutical innovators. The launched Dapagliflozin + Pioglitazone tablets is a dualaction therapy developed to progress patient outcomes and overall wellbeing.”
As per an analysis by a market research firm Phamarack, till October
2024 the Indian anti-diabetic drug market was valued around ₹17,000
crore and in a realistic scenario it is projected to expand at a CAGR of
6.5 per cent.